Kalvista Pharmaceuticals Inc KALV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 3:03 PM EDT
12.13quote price arrow down-0.01 (-0.10%)
Volume
68,062
52 week range
7.21 - 16.88
Loading...
  • Open12.18
  • Day High12.28
  • Day Low11.97
  • Prev Close12.14
  • 52 Week High16.88
  • 52 Week High Date02/01/24
  • 52 Week Low7.21
  • 52 Week Low Date11/13/23

Key Stats

  • Market Cap511.639M
  • Shares Out42.19M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-1.06

KEY STATS

  • Open12.18
  • Day High12.28
  • Day Low11.97
  • Prev Close12.14
  • 52 Week High16.88
  • 52 Week High Date02/01/24
  • 52 Week Low7.21
  • 52 Week Low Date11/13/23
  • Market Cap511.639M
  • Shares Out42.19M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • YTD % Change-1.06

RATIOS/PROFITABILITY

  • EPS (TTM)-3.14
  • P/E (TTM)-3.86
  • Fwd P/E (NTM)-4.45
  • EBITDA (TTM)-122.933M
  • ROE (TTM)-79.33%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-990.38%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kalvista Pharmaceuticals Inc

 

Profile

MORE
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting the disease hereditary angioedema (HAE). The Company is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved target enrollment for the...
Brian Pereira M.D.
Independent Non-Executive Chairman of the Board
Benjamin Palleiko
Chief Executive Officer, Director
Address
55 Cambridge Pkwy Ste 901E
Cambridge, MA
02142-1234
United States

Top Peers

SYMBOLLASTCHG%CHG
ALT
Altimmune Inc
7.13-0.23-3.12%
NKTX
Nkarta Inc
6.75-0.35-4.93%
LBPH
Longboard Pharmaceuticals Inc
22.12+1.52+7.38%
ATXS
Astria Therapeutics Inc
9.84+0.07+0.72%
ALLO
Allogene Therapeutics Inc
2.92-0.09-3.16%